enGene Holdings Inc.
NASDAQ:ENGNBiotechnology
-$0.02 today
- Market cap
- $123.98M
- Beta
- -0.29
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.95
Volume 2.81M
Average 1.58M
ENGN Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
enGene Holdings Inc.NASDAQ: ENGN
Operating Expenses · Q2 FY2026 · quarter ended Apr 2026
Operating expenses grows, but more slowly than its trailing trend
Q2 FY2026 operating expenses of $31.79M rose 17.2% year over year, behind the +50.3% change in trailing-twelve-month operating expenses. Sequentially, it rose 2.6% from the prior quarter. Over 3 fiscal years it compounded at +85.1% a year.
Context
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +17.2% toward the trailing-twelve-month pace of +50.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 123.17M USD
- Year-over-year change
- +97.7%
- 4-year CAGR
- +66.9%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | 123.17M | +97.7% |
| FY2024 | 2024-10-31 | 62.3M | +139.1% |
| FY2023 | 2023-10-31 | 26.06M | +34.1% |
| FY2022 | 2022-10-31 | 19.43M | +22.4% |
| FY2021 | 2021-10-31 | 15.87M | — |
Operating Expenses vs competitors
How ENGN compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +50.3% is the 2nd highest of 10, against a peer median of -11.1%.
- Over three fiscal years its annual growth of +85.1% compares with a peer median of +13.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $203.15M USD | +11.1% | +13.5% | — | |
| LTM Mar 2026 | $172.43M USD | +63.7% | +67.8% | — | |
| LTM Mar 2026 | $164.05M USD | +44.9% | +13.2% | — | |
| LTM Mar 2026 | $150.13M USD | -11.1% | -27.1% | 69.9% | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $132.21M USD | +50.3% | +85.1% | — |
| LTM Mar 2026 | $101.75M USD | +11.1% | -1.4% | 149.4% | |
| LTM Mar 2026 | $87.2M USD | — | +16.9% | 9463.1% | |
| LTM Mar 2026 | $85.57M USD | -14.7% | +14.9% | 2227.3% | |
| LTM Mar 2026 | $81.97M USD | -16.5% | +2.5% | 227697.2% | |
| LTM Mar 2026 | CHF 68.45M CHF | -14.4% | -1.1% | 1849.0% | |
| LTM Mar 2026 | -$55.19M USD | -179.1% | +31.6% | — | |
| Peer median (excluding ENGN) | — | -11.1% | +13.3% | 2038.1% | |
Competitors are the stored peer set for ENGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 12.46M | 15.47M | 16.46M | 38.32M | 94.48M |
| Selling, General & Admin | 3.16M | 3.26M | 8.47M | 23.98M | 28.69M |
| Operating Expenses | 15.87M | 19.43M | 26.06M | 62.3M | 123.17M |
| Depreciation & Amortization | 272K | 238K | 175K | 323K | 509K |
| EBITDA | (18.15M) | (22.78M) | (94.77M) | (52.04M) | (113.8M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (15.87M) | (19.43M) | (26.06M) | (62.3M) | (123.17M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 25K | 129K | 1.12M | 10.41M | 9.43M |
| Interest Expense | 5.02M | 1.42M | 4.95M | 2.8M | 2.99M |
| Other Income / Expenses | (7.57M) | (5.01M) | (73.84M) | 7.14M | 5.86M |
| Income Before Tax | (23.44M) | (24.44M) | (99.9M) | (55.16M) | (117.3M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 22K | 17K | (19K) | 0 |
| Net Income | (23.44M) | (24.46M) | (99.92M) | (55.14M) | (117.3M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.01) | 0.00 | (4.24) | (1.46) | (2.29) |
| EPS (Diluted) | (0.01) | 0.00 | (4.24) | (1.46) | (2.29) |
| Weighted Avg Shares | 15.81M | 15.81M | 23.56M | 44.64M | 51.12M |
| Weighted Avg Shares (Diluted) | 15.81M | 15.81M | 23.56M | 44.64M | 51.12M |
enGene Holdings Inc.
NASDAQ:ENGN
Intrinsic Alpha fair value
Locked
Current Price
$1.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.